Literature DB >> 535126

Mathematical modeling -- guide to high-dose methotrexate infusion therapy.

S D Reich.   

Abstract

A mathematical model that describes methotrexate pharmacokinetics has been refined for use as a guide to dose escalation during high-dose methotrexate infusion therapy. Parameters for the model are adjusted for a patients by the SAAM computer program of Berman and Weiss, on the basis of plasma concentrations obtained during the initial course of therapy. Various dose escalations can be simulated by the computer and a print-out of predicted plasma concentrations obtains. The model has been used successfully to predict plasma concentrations after high-dose infusions in patients, including those with abnormal creatinine clearances. The program is designed to allow comparisons among infusions of any duration. This can be helpful when a change from a 24-hour infusion to a 6-hour infusion is contemplated for a patient. Deviations of observed values from those predicted are used to warn of the possibility of delayed toxicity secondary to methotrexate and alert the physician that increased amounts of rescue agent may be required.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 535126     DOI: 10.1007/BF00254416

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  29 in total

1.  Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man.

Authors:  P R Leme; P J Creaven; L M Allen; M Berman
Journal:  Cancer Chemother Rep       Date:  1975 Jul-Aug

2.  Mathematic models of cell synchrony and drug scheduling.

Authors:  A j Valleron
Journal:  Cancer Treat Rep       Date:  1976-12

3.  The prevention of methotrexate toxicity by thymidine infusions in humans.

Authors:  W D Ensminger; E Frei
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

4.  Pharmacokinetics of methotrexate.

Authors:  D H Huffman; S H Wan; D L Azarnoff; B Hogstraten
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents.

Authors:  W J Jusko
Journal:  J Pharm Sci       Date:  1971-06       Impact factor: 3.534

6.  Methotrexate tissue distribution: prediction by a mathematical model.

Authors:  D S Zaharko; R L Dedrick; K B Bischoff; J A Longstreth; V T Oliverio
Journal:  J Natl Cancer Inst       Date:  1971-04       Impact factor: 13.506

7.  Incidence of drug-related deaths secondary to high-dose methotrexate and citrovorum factor administration.

Authors:  D D Von Hoff; J S Penta; L J Helman; M Slavik
Journal:  Cancer Treat Rep       Date:  1977-07

8.  Inhibition of renal tubular transport of methotrexate by probenecid.

Authors:  R S Bourke; G Chheda; A Bremer; O Watanabe; D B Tower
Journal:  Cancer Res       Date:  1975-01       Impact factor: 12.701

9.  Weekly high-dose methotrexate-citrovorum factor in osteogenic sarcoma: pre-surgical treatment of primary tumor and of overt pulmonary metastases.

Authors:  N Jaffe; E Frei; D Traggis; H Watts
Journal:  Cancer       Date:  1977-01       Impact factor: 6.860

10.  The relative contribution of drug concentration and duration of exposure to mouse bone marrow toxicity during continuous methotrexate infusion.

Authors:  H M Pinedo; D S Zaharko; J Bull; B A Chabner
Journal:  Cancer Res       Date:  1977-02       Impact factor: 12.701

View more
  4 in total

1.  Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.

Authors:  C Wolfrom; R Hepp; R Hartmann; H Breithaupt; G Henze
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Dose-dependent pharmacokinetics and cancer chemotherapy.

Authors:  G Powis; M M Ames; J S Kovach
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

3.  Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.

Authors:  H Iven; H Brasch; J Engster
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

4.  Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.

Authors:  F Lokiec; O Poirier; C Gisselbrecht; M Marty; M Boiron; Y Najean
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.